DOTA-GPC3 targeting peptide 2 (Sequence 30) is a RDC peptide targeting GPC3, with K d of 0.3 nM. DOTA-GPC3 targeting peptide 2 is composed of DOTA and GPC3 targeting peptide 2. DOTA-GPC3 targeting peptide 2 can be labeled with radioactive elements [1].
In Vitro, DOTA-GPC3 targeting peptide 2 is used to achieve high affinity and high selectivity in binding to the GPC3 protein. GPC3 is an overexpressed tumor-associated antigen in various solid tumors (especially hepatocellular carcinoma), and it is an important drug target[1].
References:
[1]. Takeru Ehara, et al. Peptide compositions targeting glypican-3 and uses thereof. WO2024252336A1. WIPO (PCT). 2024-06-06.
In Vitro, DOTA-GPC3 targeting peptide 2 is used to achieve high affinity and high selectivity in binding to the GPC3 protein. GPC3 is an overexpressed tumor-associated antigen in various solid tumors (especially hepatocellular carcinoma), and it is an important drug target[1].
References:
[1]. Takeru Ehara, et al. Peptide compositions targeting glypican-3 and uses thereof. WO2024252336A1. WIPO (PCT). 2024-06-06.